Delayed Oxaliplatin-Related Severe Neurotoxicity in Metastatic Colorectal Cancer: A Case Report.

chemotherapy coasting phenomenon colorectal cancer oxaliplatin peripheral neuropathy

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jan 2023
Historique:
accepted: 10 01 2023
entrez: 13 2 2023
pubmed: 14 2 2023
medline: 14 2 2023
Statut: epublish

Résumé

In patients receiving oxaliplatin-based chemotherapy, resulting in frequent peripheral neuropathy and requiring long-term management, anticancer drug-induced platinum-based peripheral neuropathy (mixed motor, sensory, and autonomic neuropathy) can result in the coasting phenomenon in which the symptoms worsen temporarily after two to three weeks, even after the cessation of the drug. The coasting phenomenon is difficult to manage due to the unpredictable nature of the symptoms. We encountered a patient with grade 3 peripheral neuropathy that developed rapidly in the second cycle after the treatment to switch from mFOLFOX6/bevacizumab to FOLFIRI/aflibercept. Supportive care with duloxetine was unsuccessful in this patient. Herein, we report the case.

Identifiants

pubmed: 36779106
doi: 10.7759/cureus.33578
pmc: PMC9909361
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e33578

Informations de copyright

Copyright © 2023, Iimura et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Clin Oncol. 2000 Aug;18(16):2938-47
pubmed: 10944126
Curr Treat Options Neurol. 2011 Apr;13(2):180-90
pubmed: 21191824
Gan To Kagaku Ryoho. 2013 Sep;40(9):1189-93
pubmed: 24047777
Neurology. 1988 Mar;38(3):488-90
pubmed: 3347355
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
JAMA. 2013 Apr 3;309(13):1359-67
pubmed: 23549581
J Clin Oncol. 2006 Jan 20;24(3):394-400
pubmed: 16421419
Anticancer Drugs. 2006 Jan;17(1):103-5
pubmed: 16317297

Auteurs

Yohei Iimura (Y)

Department of Pharmacy, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, JPN.

Naoki Furukawa (N)

Department of Pharmacy, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, JPN.

Seiichiro Kuroda (S)

Department of Pharmacy, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, JPN.

Classifications MeSH